Gilead was the owner of an SPC for a combination of two actives, namely tenofovir and emtricitabine, which they market as Truvada®, which Teva and others wished to revoke. Interestingly, Gilead also sells tenofovir alone in the absence of an SPC. In accordance with...
Patents, Supplementary Protection Certificates (SPCs) and the Unitary Patent Court (UPC) Trade Marks and Designs Copyright Exhaustion of Rights Please click on one of the hyperlinks above to go to the particular guidance note. The overarching intention of the...
What Are GMO and Why Are They Regulated? Genetically modified organisms are heavily regulated in Europe and indeed most of the Western hemisphere. In Europe this is governed by Directive 2001/18/EC on the deliberate release of GMOs into the environment (the “GMO...
NDAs A non-disclosure agreement (NDA) is a legal contract between two or more parties that outlines confidential material, knowledge or information that the concerned parties wish to share with one another but wish to restrict access to third parties. Clients often...
In Jushi v OCV, Jushi Group Co., Ltd applied to the Intellectual Property Enterprise Court to revoke European Patent 1831118 in the name of OCV Intellectual Capital LLC. Jushi alleged that the patent lacked novelty and was obvious over US Patent Application No....
Recent Comments